Hikal (HIKAL) Stock Overview
Manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals indusries. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
HIKAL Community Fair Values
See what others think this stock is worth. Follow their fair value or set your own to get alerts.
Hikal Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹243.14 |
| 52 Week High | ₹456.75 |
| 52 Week Low | ₹218.00 |
| Beta | 0.46 |
| 1 Month Change | 3.17% |
| 3 Month Change | -7.23% |
| 1 Year Change | -44.48% |
| 3 Year Change | -36.46% |
| 5 Year Change | 43.40% |
| Change since IPO | 1,572.98% |
Recent News & Updates
Hikal Limited's (NSE:HIKAL) CEO Might Not Expect Shareholders To Be So Generous This Year
Sep 17The Price Is Right For Hikal Limited (NSE:HIKAL) Even After Diving 25%
Aug 14Recent updates
Shareholder Returns
| HIKAL | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 9.1% | -0.7% | -0.8% |
| 1Y | -44.5% | -2.8% | -2.0% |
Return vs Industry: HIKAL underperformed the Indian Pharmaceuticals industry which returned -2.8% over the past year.
Return vs Market: HIKAL underperformed the Indian Market which returned -2% over the past year.
Price Volatility
| HIKAL volatility | |
|---|---|
| HIKAL Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in IN Market | 8.5% |
| 10% least volatile stocks in IN Market | 3.0% |
Stable Share Price: HIKAL has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: HIKAL's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 2,062 | Sameer Hiremath | www.hikal.com |
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals indusries. It operates through two segments, Pharmaceuticals and Crop Protection. The company also manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT.
Hikal Limited Fundamentals Summary
| HIKAL fundamental statistics | |
|---|---|
| Market cap | ₹29.89b |
| Earnings (TTM) | ₹101.00m |
| Revenue (TTM) | ₹16.99b |
Is HIKAL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HIKAL income statement (TTM) | |
|---|---|
| Revenue | ₹16.99b |
| Cost of Revenue | ₹8.31b |
| Gross Profit | ₹8.69b |
| Other Expenses | ₹8.58b |
| Earnings | ₹101.00m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.82 |
| Gross Margin | 51.12% |
| Net Profit Margin | 0.59% |
| Debt/Equity Ratio | 57.0% |
How did HIKAL perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/06 22:29 |
| End of Day Share Price | 2025/12/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hikal Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | Batlivala & Karani Securities India Pvt. Ltd. |
| Kameswari V. S. Chavali | FirstCall Research |
